2,580 Shares in TransMedics Group, Inc. (NASDAQ:TMDX) Purchased by SG Americas Securities LLC

SG Americas Securities LLC acquired a new stake in shares of TransMedics Group, Inc. (NASDAQ:TMDX) during the fourth quarter, HoldingsChannel.com reports. The institutional investor acquired 2,580 shares of the company’s stock, valued at approximately $204,000.

A number of other institutional investors have also added to or reduced their stakes in the stock. Yarbrough Capital LLC purchased a new stake in shares of TransMedics Group in the 4th quarter valued at about $201,000. RiverPark Advisors LLC lifted its position in TransMedics Group by 19.5% during the fourth quarter. RiverPark Advisors LLC now owns 1,319 shares of the company’s stock valued at $104,000 after purchasing an additional 215 shares during the last quarter. Harbour Capital Advisors LLC lifted its position in TransMedics Group by 1.7% during the fourth quarter. Harbour Capital Advisors LLC now owns 8,371 shares of the company’s stock valued at $627,000 after purchasing an additional 140 shares during the last quarter. Vanguard Group Inc. grew its stake in TransMedics Group by 1.7% in the 3rd quarter. Vanguard Group Inc. now owns 1,814,442 shares of the company’s stock worth $99,341,000 after buying an additional 29,798 shares in the last quarter. Finally, American Century Companies Inc. increased its holdings in shares of TransMedics Group by 271.2% in the 3rd quarter. American Century Companies Inc. now owns 486,956 shares of the company’s stock worth $26,661,000 after buying an additional 355,755 shares during the last quarter. Hedge funds and other institutional investors own 99.67% of the company’s stock.

Analysts Set New Price Targets

A number of equities research analysts have weighed in on TMDX shares. Piper Sandler initiated coverage on TransMedics Group in a research report on Thursday, March 28th. They set an “overweight” rating and a $95.00 price target on the stock. Morgan Stanley raised their price objective on TransMedics Group from $75.00 to $95.00 and gave the company an “equal weight” rating in a report on Wednesday, February 28th. JPMorgan Chase & Co. upped their target price on TransMedics Group from $87.00 to $105.00 and gave the stock an “overweight” rating in a research note on Tuesday, February 27th. Finally, Oppenheimer lifted their price target on shares of TransMedics Group from $92.00 to $105.00 and gave the stock an “outperform” rating in a research note on Tuesday, February 27th. One investment analyst has rated the stock with a hold rating and six have issued a buy rating to the company’s stock. Based on data from MarketBeat, the stock currently has an average rating of “Moderate Buy” and an average target price of $102.00.

TransMedics Group Trading Down 2.3 %

Shares of NASDAQ TMDX opened at $91.82 on Friday. The company has a market cap of $3.00 billion, a PE ratio of -119.25 and a beta of 1.99. The company has a debt-to-equity ratio of 3.69, a quick ratio of 8.49 and a current ratio of 9.30. The firm’s 50 day moving average price is $82.77 and its 200-day moving average price is $72.03. TransMedics Group, Inc. has a 52-week low of $36.42 and a 52-week high of $99.63.

TransMedics Group (NASDAQ:TMDX) last released its quarterly earnings data on Monday, February 26th. The company reported $0.12 EPS for the quarter, topping the consensus estimate of ($0.10) by $0.22. The company had revenue of $81.20 million during the quarter, compared to the consensus estimate of $68.49 million. TransMedics Group had a negative return on equity of 2.35% and a negative net margin of 10.36%. TransMedics Group’s revenue for the quarter was up 158.6% on a year-over-year basis. During the same period last year, the company earned ($0.21) EPS. On average, equities research analysts expect that TransMedics Group, Inc. will post -0.14 EPS for the current fiscal year.

Insider Buying and Selling at TransMedics Group

In other TransMedics Group news, CEO Waleed H. Hassanein sold 12,000 shares of the stock in a transaction that occurred on Wednesday, April 10th. The shares were sold at an average price of $95.09, for a total value of $1,141,080.00. Following the transaction, the chief executive officer now directly owns 74,087 shares in the company, valued at $7,044,932.83. The transaction was disclosed in a legal filing with the Securities & Exchange Commission, which can be accessed through this hyperlink. In related news, insider Tamer I. Khayal sold 2,330 shares of TransMedics Group stock in a transaction that occurred on Tuesday, January 23rd. The stock was sold at an average price of $90.09, for a total transaction of $209,909.70. Following the sale, the insider now owns 14,375 shares of the company’s stock, valued at approximately $1,295,043.75. The sale was disclosed in a filing with the Securities & Exchange Commission, which can be accessed through the SEC website. Also, CEO Waleed H. Hassanein sold 12,000 shares of TransMedics Group stock in a transaction that occurred on Wednesday, April 10th. The shares were sold at an average price of $95.09, for a total transaction of $1,141,080.00. Following the sale, the chief executive officer now owns 74,087 shares in the company, valued at approximately $7,044,932.83. The disclosure for this sale can be found here. Insiders sold a total of 125,408 shares of company stock worth $10,606,501 in the last three months. 6.70% of the stock is currently owned by company insiders.

TransMedics Group Profile

TransMedics Group, Inc, a commercial-stage medical technology company, engages in transforming organ transplant therapy for end-stage organ failure patients in the United States and internationally. The company offers Organ Care System (OCS), a portable organ perfusion, optimization, and monitoring system that utilizes its proprietary and customized technology to replicate near-physiologic conditions for donor organs outside of the human body.